Carboplatin and Paclitaxel Plus ASA404 as First-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Multicenter Single Arm Phase II Trial (SAKK 15/08)

Martin Früh(University of Bern), Miklos Pless(Ontario Institute for Cancer Research), Mathew Simcock(Swiss Group For Clinical Cancer Research), Pierre Fustier(Centre Jean Perrin), Richard Cathomas(Kantonsspital Graubünden), Marco Siano(University of St.Gallen), Fatima Krasniqi(University Hospital of Basel), Alfred Zippelius(University of Basel), Erika Küttel(University of Bern), Christoph Mamot(Kantonsspital Aarau), Daniel Rauch(Washington University in St. Louis), Andreas Erdmann(Kantonsspital Baden), Gregor Tscherry(Spital Uster)
Clinical Lung Cancer
May 24, 2012
10.1016/j.cllc.2012.04.001
Cited by 23

Related Papers

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
|Nature Medicine|2018|1.2k
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
|Immunity|2018|937